GlaxoSmithKline (GSK) has promised to make its clinical trial data available to the scientific community as part of its efforts to provide increased transparency and cooperation.

GSK was fined $3 billion in the United States for concealing safety issues. The drug maker pleaded guilty in July 2012 to promoting the drugs Paxil and Wellbutrin for unapproved uses. GSK also withheld safety data regarding the diabetes drug, Avandia, from the U.S. Food & Drug Administration (FDA), Medical News Today said.

The $3 billion settlement covered criminal fines and civil settlements with state and federal governments and involved 10 medications, including Advair, Avandia, Wellbutrin, and Paxil, according to Medical News Today. GSK was also found guilty of bribing doctors.

GSK says that its web site–The GlaxoSmithKline Clinical Study Register–now includes the result of summaries from as many as 4,500 clinical trials. The company also plans to publish the results of all clinical trials that evaluate its medications, regardless of the findings, to peer-reviewed academic journals, Medical News Today noted.